Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics reported new clinical data for its anti-cancer antibody HMBD-002 at the American Association for Cancer Research Annual Meeting, highlighting results from a completed phase I trial in 48 patients with advanced cancers across six U.S. centers. The therapy, alone and in combination with pembrolizumab, was safe and well tolerated at doses up to 1,400 mg weekly, with no additional toxicity seen in the combination arm.
Several patients remained on treatment for extended periods or experienced meaningful tumor shrinkage, providing early signs of biological activity in a heavily pretreated population where many novel cancer drugs fail at this stage. Biomarker analyses showed HMBD-002 triggered an immunostimulatory response consistent with its VISTA-blocking mechanism, and Percheron plans to present new preclinical data at the upcoming ASCO meeting and to launch a new clinical trial of HMBD-002 in the second half of 2026, underscoring its strategic push to advance this asset in immuno-oncology.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases. The company is advancing a pipeline that includes HMBD-002, an immuno-oncology candidate targeting the VISTA immune checkpoint, positioning it within the highly competitive cancer immunotherapy market.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.09M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.